

## Surveillance Optimization to Detect Poliovirus in the Pre-Eradication Era: a Modelling Study of England and Wales

Journal:	<i>Epidemiology and Infection</i>
Manuscript ID	HYG-OM-10192-Feb-20.R1
Manuscript Type:	Original Paper
Date Submitted by the Author:	n/a
Complete List of Authors:	O'Reilly, Kathleen; London School of Hygiene & Tropical Medicine, Epidemiology and Population Health Grassly, N; Imperial College London Allen, David; London School of Hygiene and Tropical Medicine, Pathogen Molecular Biology Department Bannister-Tyrrell, M; AU Vet Med Library Cameron, Angus; AU Vet Med Library Carrion Martin, I; MSF Ramsay, Mary; Health Protection Agency, Health Protection Agency Pebody, Richard; Public Health England Colindale, Respiratory Diseases Department Zambon, Maria; Public Health England
Keyword:	Polio, Surveillance, Surveillance system, Virology (human) and epidemiology
Abstract:	Surveillance for acute flaccid paralysis (AFP) cases is essential for polio eradication. However, as most poliovirus infections are asymptomatic and some regions of the world are inaccessible additional surveillance tools require development. Within England and Wales we demonstrate how inclusion of environmental sampling (ENV) improves the sensitivity of detecting either wild or vaccine derived polioviruses (VDPVs) when compared to current surveillance. Statistical modelling was used to estimate the spatial risk of wild and VDPV importation and circulation in England and Wales. We estimate the sensitivity of each surveillance mode to detect poliovirus and the probability of being free from poliovirus, defined as being below a pre-specified prevalence of infection. Poliovirus risk was higher within local authorities in Manchester, Birmingham, Bradford and London. The sensitivity of detecting wild poliovirus within a given month using AFP and enterovirus surveillance was estimated to be 0.096 (95% CI 0.055, 0.134). Inclusion of ENV in the 3 highest risk local authorities and a site in London increased surveillance sensitivity to 0.192 (95% CI 0.191 0.193). The sensitivity of ENV strategies can be compared using the framework by varying sites and the frequency of sampling. The probability of being free from poliovirus slowly increased from the date of the last case in 1993. ENV within areas thought to have the highest risk improves detection of poliovirus, and has the potential to improve confidence in the polio-free status of England and Wales and detect VDPVs.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# 1 Surveillance Optimization to Detect Poliovirus in the Pre- 2 Eradication Era: a Modelling Study of England and Wales

3  
4 K. M. O'Reilly<sup>1,2,3\*</sup>, N. C. Grassly<sup>3</sup>, D. J. Allen<sup>4,5,6</sup>, M. Bannister-Tyrrell<sup>7</sup>, A. Cameron<sup>8</sup>,  
5 A. I. Carrion Martin<sup>6,9</sup>, M. Ramsay<sup>6</sup>, R. Pebody<sup>6</sup>, M. Zambon<sup>6</sup>

6  
7 <sup>1</sup> Department of Infectious Disease Epidemiology, London School of Hygiene &  
8 Tropical Medicine, London, UK

9 <sup>2</sup> Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene  
10 & Tropical Medicine, London, UK

11 <sup>3</sup> MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease  
12 Epidemiology, St Mary's Campus, Imperial College London, London, UK

13 <sup>4</sup> Department of Infection Biology, London School of Hygiene and Tropical Medicine,  
14 London, UK

15 <sup>5</sup> Vaccine Centre, London School of Hygiene & Tropical Medicine, London, UK

16 <sup>6</sup> National Infection Service, Public Health England, London, UK

17 <sup>7</sup> Ausvet Europe, 3 Rue Camille Jordan, 69001 Lyon, France

18 <sup>8</sup> Ausvet, 5 Shuffrey Street, Fremantle, WA 6160, Australia

19 <sup>9</sup> European Program for Intervention Epidemiology Training (EPIET), European Centre  
20 for Disease Prevention and Control, (ECDC), Stockholm, Sweden.

21  
22 \* Corresponding author ([kathleen.oreilly@lshtm.ac.uk](mailto:kathleen.oreilly@lshtm.ac.uk))

23 Running head: Polio Surveillance in England and Wales

## 24 Summary

25 Common to many European countries, England and Wales remain at risk of poliovirus  
26 importations and must continue to carry out surveillance in the pre-eradication era.  
27 Within England and Wales we demonstrate how inclusion of environmental sampling  
28 (ENV) improves the sensitivity of detecting either wild or vaccine derived polioviruses  
29 (VDPVs) when compared to current surveillance. Statistical modelling was used to  
30 estimate the spatial risk of wild and VDPV importation and circulation in England and  
31 Wales. We estimate the sensitivity of each surveillance mode to detect poliovirus and  
32 the probability of being free from poliovirus, defined as being below a pre-specified  
33 prevalence of infection. Poliovirus risk was higher within local authorities in  
34 Manchester, Birmingham, Bradford and London. The sensitivity of detecting wild  
35 poliovirus within a given month using acute flaccid paralysisAFP and enterovirus  
36 surveillance was estimated to be 0.096 (95% CI 0.05~~57~~, 0.13~~40~~). Inclusion of ENV in  
37 the 3 highest risk local authorities and a site in London increased surveillance  
38 sensitivity to 0.~~270-192~~ (95% CI 0.~~191239~~ 0.~~304193~~). The sensitivity of ENV strategies  
39 can be compared using the framework by varying sites and the frequency of sampling.  
40 ENV placed within areas of high risk improves detection of poliovirus, and makes best  
41 use of the intensive sampling technique required.

1  
2  
3 424  
5  
6 43 **Abstract**

7  
8 44 Surveillance for acute flaccid paralysis (AFP) cases is essential for polio eradication.  
9  
10 45 However, as most poliovirus infections are asymptomatic and some regions of the  
11  
12 46 world are inaccessible additional surveillance tools require development. Within  
13  
14 47 England and Wales we demonstrate how inclusion of environmental sampling (ENV)  
15  
16 48 improves the sensitivity of detecting either wild or vaccine derived polioviruses  
17  
18 49 (VDPVs) when compared to current surveillance. Statistical modelling was used to  
19  
20 50 estimate the spatial risk of wild and VDPV importation and circulation in England and  
21  
22 51 Wales. We estimate the sensitivity of each surveillance mode to detect poliovirus and  
23  
24 52 the probability of being free from poliovirus, defined as being below a pre-specified  
25  
26 53 prevalence of infection. Poliovirus risk was higher within local authorities in  
27  
28 54 Manchester, Birmingham, Bradford and London. The sensitivity of detecting wild  
29  
30 55 poliovirus within a given month using AFP and enterovirus surveillance was estimated  
31  
32 56 to be 0.096 (95% CI 0.05~~57~~, 0.13~~40~~). Inclusion of ENV in the 3 highest risk local  
33  
34 57 authorities and a site in London increased surveillance sensitivity to 0.~~192270~~ (95%  
35  
36 58 CI 0.~~191239~~ 0.~~193304~~). The sensitivity of ENV strategies can be compared using the  
37  
38 59 framework by varying sites and the frequency of sampling. The probability of being  
39  
40 60 free from poliovirus slowly increased from the date of the last case in 1993 ~~and~~  
41  
42 61 ~~illustrated the added value of enhanced enterovirus surveillance in the 1990s~~. ENV  
43  
44 62 within areas thought to have the highest risk improves detection of poliovirus, and has  
45  
46 63 the potential to improve confidence in the polio-free status of England and Wales and  
47  
48 64 detect VDPVs.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 65 Introduction

66

67 Indigenous wild poliovirus has been not been reported within England and Wales since  
68 the 1970s [1]. The elimination of poliomyelitis was achieved largely through  
69 vaccination of children and adults, using both the oral and inactivated polio vaccines  
70 (OPV and IPV, respectively). The IPV was introduced in 1956 and was replaced by  
71 the OPV in 1962 where it was part of the routine immunisation programme. In  
72 ~~2004~~1988 the OPV was replaced by the IPV owing to the lower risk of vaccine-  
73 associated paralytic poliomyelitis (VAPP) cases. After the introduction of vaccination  
74 wild poliomyelitis cases quickly reduced in number; although sporadic imported cases  
75 of wild poliomyelitis cases have been reported within England and Wales until the  
76 1980s, emphasising the need for high immunisation rates until polio is eradicated  
77 globally [2].

78

79 Across the decades from endemicity to elimination within England and Wales,  
80 surveillance for poliomyelitis has required adaptation. Global surveillance for  
81 poliomyelitis was developed in the 1990s within the Pan American Health Organization  
82 to detect cases, focussed within polio endemic settings. All cases of acute flaccid  
83 paralysis (AFP, the typical clinical presentation of poliomyelitis) in children <15 years  
84 should be investigated, and country surveillance rates have been used to determine  
85 an adequate surveillance system. AFP surveillance was instituted throughout the  
86 United Kingdom by 1991 where children <16 years of age presenting with AFP of any  
87 aetiology were investigated for poliomyelitis [1]. The reported AFP rate was ~0.38 per  
88 100,000 and ~54% of cases had at least 1 stool sample collected for virology.  
89 Approximately 58% of AFP cases were discarded as polio and diagnosed as Guillain-

1  
2  
3 90 Barre syndrome. The comparatively low AFP reporting rate has been consistent in  
4  
5 91 subsequent years and reflects reporting rates within other high-income countries in  
6  
7 92 Western Europe [3]. To further support the evidence base for the polio-free status of  
8  
9 93 England and Wales, enterovirus surveillance (ENT) was included as part of the  
10  
11 94 poliovirus submissions in the early 2000s, where children presenting with meningitis  
12  
13 95 (a rarer clinical presentation of poliovirus) were tested for the presence of enterovirus  
14  
15 96 infection, including poliovirus [1]. However, AFP and ENT surveillance will only detect  
16  
17 97 clinical disease and as poliovirus infection is largely asymptomatic more appropriate  
18  
19 98 tools are required. Internationally, environmental sampling (ENV) for poliovirus has  
20  
21 99 been very useful in providing both evidence of elimination but also in detection of small  
22  
23 100 outbreaks and otherwise undetected transmission in IPV vaccinated ~~edion~~ populations  
24  
25  
26  
27  
28 101 (where IPV protects against poliomyelitis but provides little mucosal immunity against  
29  
30 102 infection) [4].  
31  
32

33 103  
34  
35 104 As eradication draws closer, surveillance for residual transmission and early  
36  
37 105 indications of new importations and emergence events becomes increasingly  
38  
39 106 important [5]. Each WHO regional office is carrying out a certification process for  
40  
41 107 poliomyelitis eradication, where epidemiological evidence is reviewed to ascertain the  
42  
43 108 polio-free status of each country [3]. One challenge is to assess and compare the  
44  
45 109 available evidence of being polio-free given the different epidemiological surveillance  
46  
47 110 activities and importation risk within each country. Additionally, vaccine-derived  
48  
49 111 polioviruses (VDPVs) have increased in incidence since the removal of serotype-2  
50  
51 112 from OPV in 2016. VDPVs originate from the OPV vaccine but have acquired specific  
52  
53 113 mutations that increase the probability of poliovirus infection resulting in paralysis, and  
54  
55 114 easily spreads in unvaccinated populations. Although no VDPVs have been detected  
56  
57  
58  
59  
60

1  
2  
3 115 in England and Wales, it remains essential to have sufficient surveillance to detect any  
4  
5 116 importation and transmission events.  
6  
7  
8 117

9  
10 118 We make the distinction between detection of wild poliovirus and vaccine-derived  
11  
12 119 poliovirus (VDPVs) because wild infections now consist of only serotype 1, and a  
13  
14 120 majority of VDPV infections are of serotype 2 with a lower probability of clinical  
15  
16  
17 121 disease. We assume that current surveillance activities continue and explore how  
18  
19 122 introducing ENV surveillance can supplement current activities. Using a statistical  
20  
21  
22 123 framework we aimed to answer;

- 23  
24 124 1. Where in England and Wales should ENV surveillance be implemented to  
25  
26 125 optimise detection of wild-type and VDPVs?  
27  
28 126 2. How does ENV surveillance improve the evidence that England and Wales are  
29  
30  
31 127 free from wild-type and VDPVs?  
32

33 128  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 129 Methods

130

131 Poliomyelitis cases are classified according to virus origin; wild-type poliomyelitis  
132 cases are those that have a close genetic relation to other wild-type viruses whilst  
133 vaccine-associated poliomyelitis cases have originated from the attenuated strain  
134 used in the OPV. In this analysis we consider wild-type poliovirus, which now consist  
135 only of serotype 1, and VDPVs which we assume to be of serotype 2 [6]. We do not  
136 consider vaccine-associated paralytic poliomyelitis cases or transmission from  
137 immune-deficient VPDV shedders [7]. These considerations are in line with the  
138 England and Wales National Guidelines for Polio [8].

139

140 *Estimating the spatial variation in the potential for poliovirus circulation in England and*  
141 *Wales*

142

143 Poliovirus circulation is defined as the sustained circulation through several chains of  
144 transmission of either wild-type or VDPVs within a localised area of England and  
145 Wales as a result of importation of the index infection (or case). The potential for  
146 poliovirus circulation was assumed to be the combined effect of the importation rate  
147 and the probability of local virus circulation, and was estimated for each local authority  
148 (LA). We assume that poliovirus importation varies spatially within England and Wales  
149 according to localised international migration. Importation will be driven by  
150 international travel; either residents acquiring poliovirus while abroad or through the  
151 arrival of international visitors. While the numbers of residents travelling internationally  
152 and the number of visitors is well documented at a country level, the sub-national  
153 location of both of these groups is not adequately reported. We make a simplifying

1  
2  
3 154 assumption that the location of foreign-born nationals approximates the location of  
4  
5 155 residents visiting countries and for visitors from each country. We focus on residents  
6  
7 156 from countries that have reported either wild-type or VDPVs between 2015-2017  
8  
9  
10 157 (Table 1).

11  
12 158

13  
14 159 Data on the locality of foreign-born nationals are available from census data [9]. These  
15  
16 160 data are reported at a local authority (LA) level, consisting of 326 geographical units  
17  
18 161 within England and 22 within Wales (348 in total). The travel patterns of UK residents  
19  
20 162 and visitors to the UK are available from the International Passenger Survey (IPS)  
21  
22 163 [10]. Only data for residents and visitors to Pakistan and India were available with  
23  
24 164 sufficient accuracy, the remaining countries were grouped with other countries within  
25  
26 165 a geographical region (West Africa, South East Asia, Middle East) and the numbers  
27  
28 166 were adjusted according to the proportion of the region that reside in each country.

29  
30  
31 167

32  
33 168 The probability of local poliovirus circulation (herein referred to as poliovirus  
34  
35 169 circulation) was estimated. We assumed that for each LA the probability of circulation  
36  
37 170 follows a binomial model with exposure being the number of movements between  
38  
39 171 England and Wales and each country and the probability of circulation given  
40  
41 172 introduction (supplement). Since 2004 the IPV vaccine was included in the routine  
42  
43 173 immunisation schedule, as part of the 'pentavalent' vaccine, and the OPV was phased  
44  
45 174 out. Circulation given introduction is a function of the assumed basic reproduction  
46  
47 175 number and local pentavalent coverage ~~(which includes the inactivated polio vaccine).~~  
48  
49 176 For LAs estimated to have a higher poliovirus risk the relevant water company and,  
50  
51 177 where possible, the likely sewage treatment works that would need to be sampled are  
52  
53 178 provided.

1  
2  
3 1794  
5 180 *Estimating the probability of being free from poliovirus using surveillance data*6  
7 181

8 182 Being 'free' from poliovirus is a distinct concept from elimination or eradication.

9  
10 183 Elimination is defined as the reduction to zero of the incidence of a specified disease11  
12 184 in a defined geographical area and eradication is the permanent global reduction to13  
14 185 zero of the incidence of infection. Being free from poliovirus refers to the incidence of15  
16 186 infection being below a pre-specified threshold, and the threshold is informed by17  
18 187 globally accepted indicators of surveillance. Whilst elimination was confirmed in19  
20 188 England and Wales in the 1970s, surveillance is required to detect the re-emergence21  
22 189 of polio should it be re-introduced. Comparison of different modes and efforts of23  
24 190 surveillance can be subjective, and so to quantify the quality of evidence from25  
26 191 surveillance, we estimate the probability of freedom from poliovirus [10].27  
28 19229  
30 193 We follow methods that have largely been developed in animal health [11, 124]. The31  
32 194 population is divided into LAs and the surveillance system is divided into its constituent33  
34 195 modes of surveillance (Figure 1). We then determine a 'design prevalence', which is35  
36 196 the prevalence of infection that the surveillance system is designed to detect. We use37  
38 197 the standard surveillance indicator within polio eradication of 1 AFP case (all causes)39  
40 198 per 100,000 individuals aged less than 15 years per year. As infection is likely to41  
42 199 cluster (especially if an epidemic occurs), we include this by specifying the regional43  
44 200 design prevalence of detecting at least 1 LA with poliovirus at the specified design45  
46 201 prevalence. The combined effect of risk and design prevalence is included in the47  
48 202 'effective probability of infection' [12]. Each mode of surveillance (AFP, ENT and ENV)49  
50 203 is then characterised by considering the sensitivity of detection at each stage of51  
52  
53  
54  
55  
56  
57  
58  
59  
60

204 sampling. Each is briefly described in turn below, and parameter values summarised  
205 in Table 2, and described in full in the supplement.

206

207 For AFP surveillance, the sensitivity is a product of the probability that an individual  
208 infected with poliovirus will develop symptoms consistent with AFP, which varies by  
209 serotype, the probability that an AFP case is admitted to a hospital and notified, and  
210 the probability that the case is correctly identified as poliomyelitis through collection  
211 and isolation of poliovirus in stool. This is summarised using the surveillance sensitivity  
212 per month ( $CSe_{AFP}$ ).

213

214 ENT surveillance arises from investigation of individuals accessing healthcare ~~who are~~  
215 ~~symptomatic~~ and from whom an enterovirus-positive specimen has been obtained. All  
216 NHS laboratories are requested to submit enterovirus-positive specimens for  
217 surveillance of poliovirus. ENT surveillance captures different clinical presentations,  
218 many of which are viral meningitis [13]. For infection with poliovirus, meningitis can  
219 occur in approximately 1% of clinical cases [14], with no available data on variation by  
220 serotype. In the model we assume the notification rate is as high as for presentation  
221 with AFP. A majority of clinical samples collected by ENT surveillance consist of either  
222 stool, which has good sensitivity to detect poliovirus [13], or cerebral spinal fluid  
223 samples where the sensitivity of detecting enteroviruses is lower. Between 2000-2011  
224 in the UK clinical samples to detect enterovirus infections included 5032 cerebrospinal  
225 fluid samples and 2394 gastrointestinal samples (that are most likely stool samples)  
226 [15], where 43% of all enterovirus infections were detected via gastrointestinal  
227 samples. – PCR is usually carried out on clinical specimens which has been  
228 demonstrated to be a useful method in detection of enterovirus RNA in these sample

1  
2  
3 229 types [1516]. Where enterovirus RNA is detected, further laboratory investigations will  
4  
5 230 aim to rule out poliovirus as the causative agent. To account for the variable sensitivity  
6  
7 of cerebrospinal and stool samples the sensitivity of individual clinical samples is  
8 231 assumed to have a lower confidence bound when compared to AFP surveillance  
9  
10 232 (where all clinical samples are stool). In the model the sensitivity of ENT surveillance  
11  
12 233 over a period of one month is  $CSe_{ENT}$ .  
13  
14 234  
15  
16  
17 235

18  
19 236 ENV surveillance is included in the framework by specifying whether each LA includes  
20  
21 237 ENV. For those LAs with no ENV the sensitivity of ENV to detect poliovirus is zero. As  
22  
23 238 ENV surveillance is under development in England and Wales we vary the frequency  
24  
25 239 and location of ENV to explore the effect on surveillance sensitivity. The sensitivity of  
26  
27 240 a sample is assumed to depend on the proportion of residents included in the sewage  
28  
29 241 catchment, the probability that a sample contains poliovirus if an individual is shedding  
30  
31 242 and the laboratory sensitivity which is thought to be high [17]. The sensitivity of AFP  
32  
33 243 surveillance over a period of one month is  $CSe_{ENV}$ .  
34  
35  
36  
37  
38 244

39  
40 245 The combined surveillance sensitivity of the system is calculated;  $CSSe = 1 - (1 -$   
41  
42 246  $CSe_{AFP})(1 - CSe_{ENT})(1 - CSe_{ENV})$ . Using the principal of the negative predictive value  
43  
44 247 of a test, the probability of being infection free within a given month can be calculated.  
45  
46 248 The probability of being polio free was then estimated for each month from January  
47  
48 249 1993 to present day, with the addition of ENT surveillance in 1997, and assuming ENV  
49  
50 250 in 2019. All the analysis was carried out in the software R (version 3.6.1.) and the code  
51  
52 251 to replicate the analysis is available (<https://github.com/kath-o-reilly/polio-FFI-UK>).  
53  
54  
55  
56  
57 252  
58  
59  
60

## 253 Results

254

### 255 *Spatial estimates of poliovirus risk in England and Wales*

256

257 Between 2015 and 2017 Afghanistan, Pakistan and Nigeria reported cases of wild-  
258 type poliomyelitis while Pakistan, Nigeria, Madagascar, Laos, DR Congo, Syria,  
259 Guinea and Myanmar reported cases of VDPVs. Within Pakistan and Nigeria, more  
260 visits were made by residents of England and Wales to the country than visitors from  
261 each country (Table 1). For Afghanistan, Pakistan and Nigeria a majority of visitors  
262 were visiting friends and relatives, supporting the assumption that their location will  
263 correlate with the location of foreign-born nationals.

264

265 Within England and Wales the locality of long and short term residents born outside of  
266 England and Wales varies spatially and are often focussed within cities and associated  
267 conurbations, especially Birmingham, Bradford, London, and Manchester. Coverage  
268 of the pentavalent vaccine varies across England and Wales, with an average of  
269 96.3% per LA (supplement). The LAs where foreign-born nationals are frequently  
270 located are often correlated with areas that report low pentavalent coverage. When  
271 combining these data together to estimate the probability of poliovirus circulation 21  
272 LAs comprise of over 50% of the estimated risk and several of these LAs are located  
273 within cities including Manchester, Birmingham and Greater London (Figure 2 and  
274 Table 3). Consequently, if ENV sampling were targeted within catchment areas that  
275 cover these LAs, this would be an efficient form of targeted surveillance.

276

277 *Estimating the probability of being poliovirus free from surveillance data*

1  
2  
3 278  
4  
5  
6 279 Detection of poliovirus through clinical surveillance – which is implemented in England  
7  
8 280 and Wales - is low as clinical disease is a minority of infections. The probability of  
9  
10 281 detecting one infection from clinical surveillance (the combined use of AFP and ENT  
11  
12 282 surveillance) is estimated to be 0.003245 (95% CI 0.0017783 0.0048179) for wild-type  
13  
14 283 poliovirus and 0.00033669 (95% CI 0.00016075 0.000641) for VDPVs. The freedom  
15  
16 284 from infection model uses these values along with estimates of ~~the risk of~~  
17  
18 285 poliovirus circulation within each LAs to estimate the sensitivity of each mode of  
19  
20 286 surveillance per month. Using the information available on sampling sensitivity and  
21  
22 287 surveillance activities within England and Wales, the sensitivity of detecting wild-type  
23  
24 288 poliovirus using AFP and ENT surveillance at the specified design prevalence within  
25  
26 289 a given month was estimated to be 0.096 (95% CI 0.0557 0.1340), and lower for VDPV  
27  
28 290 (0.011120 with 95% CI 0.00538 0.0210).  
29  
30  
31  
32

33 291  
34  
35 292 We explore several scenarios for the use of ENV in England and Wales. ENV  
36  
37 293 surveillance has a differing profile to clinical surveillance as it is highly sensitive where  
38  
39 294 it is implemented but is limited by the size of the sewage catchment area included in  
40  
41 295 sampling. Implementing monthly ENV in Birmingham, Manchester and Bradford (the  
42  
43 296 LAs with highest risk of importation and circulation, strategy A (Table 3)) the sensitivity  
44  
45 297 of ENV ( $CSe_{ENV}$ ) is estimated to be 0.0868 (95% CI 0.0867, 0.0869). Sampling in the  
46  
47 298 three high risk sites and Beckton (strategy B London) has an estimated sensitivity of  
48  
49 299 0.192 (95% CI 0.191, 0.193). Performing fortnightly instead of monthly sampling in the  
50  
51 300 same sites would result in only a moderate increase in sensitivity despite a doubling  
52  
53 301 of samples. ENV surveillance capturing LAs that comprise 50% of the total risk  
54  
55 302 (strategy C) would correspond to an estimated sensitivity of 0.32 (95% CI 0.31, 0.33),  
56  
57  
58  
59  
60

1  
2  
3 303 and would consist of 10 ENV samples per month. Including monthly ENV surveillance  
4  
5 304 within Birmingham, Manchester and Bradford would increase the total sensitivity of  
6  
7 305 detecting wild-type poliovirus to 0.174 (95% CI 0.139 0.209) and with the addition of  
8  
9  
10 306 Beckton (London) the sensitivity would increase to 0.270 (95% CI 0.239 0.301), with  
11  
12 307 slightly lower values for VDPV surveillance.  
13  
14

15 308

16  
17 309 We then estimate ~~of~~ the probability that England and Wales was free from wild-type  
18  
19 310 poliovirus, given the operating surveillance and the absence of cases or infections,  
20  
21 311 from 1993 to present day. The probability of being poliovirus free increases over time  
22  
23 312 from the date of the last reported case of poliomyelitis in England and Wales in 1993.  
24  
25 313 The introduction of ENT surveillance in 1997 was estimated to moderately improve  
26  
27 314 the rate of increase in the probability of being free from poliovirus due to the higher  
28  
29 315 sensitivity (Figure 3). There was no noticeable difference in the temporal change in  
30  
31 316 probabilities when different importation risks were assumed or when using the  
32  
33 317 population movements from IPS data versus assuming a constant importation rate.  
34  
35 318 Inclusion of ENV into the estimates for the latter years would not change the estimates  
36  
37 319 of England and Wales being polio free, largely because the estimates are already  
38  
39 320 above 99.9%. A comparison of VDPV is also shown, but it is noted that VDPVs have  
40  
41 321 never been reported in England and Wales. The lower sensitivity of surveillance  
42  
43 322 means that the probability of being infection free increases but at a lower rate.  
44  
45 323 Inclusion of ENV in surveillance improves sensitivity to detect VDPVs, meaning that  
46  
47 324 surveillance will also improve detection of introduced VDPVs.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 326 Discussion

327

328 In the final stages of polio eradication, surveillance for circulation of polioviruses  
329 remains essential. The practicalities of surveillance are becoming increasingly  
330 challenging owing to the reduced incidence of disease, an increase in the variety of  
331 risks that need to be considered and an increasingly connected world that potentially  
332 increases risk through population movement. The findings presented here illustrate  
333 the potential weaknesses of using clinical surveillance alone to detect poliovirus in  
334 England and Wales, and the added benefits of incorporating ENV. Using ENV in an  
335 informed, targeted manner has the potential to greatly enhance surveillance for  
336 polioviruses, thus expedite detection of importation events.

337

338 The approach described here assumes that spatial variation in risk within England and  
339 Wales can be quantified using data and used to inform where ENV should be targeted  
340 to maximise detection. ~~To the authors knowledge this is the first attempt to quantify~~  
341 ~~the spatial variation in poliovirus risk within a polio-free setting.~~ Use of spatial risk  
342 mapping helps prioritize ENV sampling according to risk and estimation of surveillance  
343 sensitivity enable comparison of sampling strategies. This has been especially useful  
344 in developing the poliovirus environmental sampling strategy within England and  
345 Wales. Sampling sewage from the highest risk LAs targets surveillance within areas  
346 most likely to be exposed to poliovirus, and sampling within a large London sewage  
347 treatment works is advantageous as it covers a considerable proportion of the  
348 population with just one ENV sample. Within a pilot scheme implemented between  
349 2016-2017 Sabin poliovirus was detected in several samples, illustrating that  
350 poliovirus can be detected within a large sewage plant [[1617](#)]. Sampling in more sites

1  
2  
3 351 largely out-performs more frequent sampling in the same sites, but may be sensitive  
4  
5 352 to our assumptions on the duration of poliovirus shedding.  
6  
7  
8 353

9  
10 354 Much of the spatial variation in risk is due to movements between England and Wales  
11  
12 355 and countries that have or are currently reporting wild-type and VDPV poliomyelitis  
13  
14 356 cases. We assume that migration at a LA level is similar to the location of foreign-born  
15  
16 357 nationals within the census. Data from IPS supports this assumption, as most  
17  
18 358 residents report visiting friends and family when visiting Afghanistan, Pakistan and  
19  
20 359 Nigeria. There are less data to quantify movements from Laos, DR Congo, Guinea,  
21  
22 360 Myanmar and Syria, which have all reported poliomyelitis cases in recent years. With  
23  
24 361 the emergence of VDPVs in Africa the risk of importation is likely to have only  
25  
26 362 increased marginally due to the low number of movements between here and England  
27  
28 363 and Wales. Should the incidence of VDPVs increase in Asia (and especially Pakistan  
29  
30 364 which has both ongoing wild-type and VDPV transmission, and much more travel to  
31  
32 365 England and Wales) the risk of importation into the UK-England and Wales will further  
33  
34 366 increase ~~due to many more movements between the UK and Asia~~. As VDPVs have a  
35  
36 367 lower symptomatic rate the addition of ENV to clinical surveillance becomes even  
37  
38 368 more important. Vaccination coverage within LAs influences the likelihood of virus  
39  
40 369 circulation, and ensuring that coverage remains above 90% across communities  
41  
42 370 remains essential. It is therefore a concern that some LAs, especially in London  
43  
44 371 boroughs, consistently report coverage below this value and these are often the same  
45  
46 372 LAs with a higher proportion of foreign-born residents. Risk factors associated with  
47  
48 373 low pentavalent coverage have not been specifically explored in England and Wales,  
49  
50 374 but studies for other vaccines suggest that ethnicity and socio-economic factors are  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 375 associated with lower coverage [1718]. Strategies to improve vaccination rates within  
4  
5 376 these underserved communities should therefore be prioritised.  
6  
7

8 377

9  
10 378 Estimates of the probability of being infection free are moderately sensitive to  
11  
12 379 assumptions on the probability of importation, which remain uncertain within England  
13  
14 380 and Wales. Visitors to countries that are at risk of poliovirus are recommended to  
15  
16 381 receive a booster of IPV/pentavalent vaccine, and visitors from at-risk countries are  
17  
18 382 required to provide evidence of recent vaccination history as part of the continued  
19  
20 383 Public Health Emergency of International Concern for poliomyelitis. Visitors to Saudi  
21  
22 384 Arabia, as part of religious pilgrimages (Hajj or Umrah) are recommended to receive  
23  
24 385 vaccinations [1819]. Consequently, substantial efforts are put in place to reduce the  
25  
26 386 risk of poliovirus importations to England and Wales, but the risk remains, as illustrated  
27  
28 387 by recent importation events within other high income countries [1920, 2021].  
29  
30  
31  
32

33 388

34  
35 389 There are several caveats to the analysis that may warrant further research. We have  
36  
37 390 not considered the risks associated with laboratory release, which are currently  
38  
39 391 considered low, but the relative risks associated with Polio Essential Facilities located  
40  
41 392 in England and Wales will increase as polio eradication approaches the post-  
42  
43 393 certification phase [2122]. We do not consider the risks associated with transmission  
44  
45 394 of polioviruses from immune-compromised individuals shedding iVDPVs; despite  
46  
47 395 intensive study there has only been a small handful of transmission events recorded  
48  
49 396 and there is only one reported individual within the UK known to shed iVDPV [2223].  
50  
51  
52 397 Further exploration of ENT surveillance for detecting polioviruses is warranted, as  
53  
54 398 current stool sampling is limited even though the sensitivity of detection is high and  
55  
56 399 the sampling is non-invasive. Populations of unvaccinated adults may pose a risk  
57  
58  
59  
60

1  
2  
3 400 within specific geographical communities but currently there is little information to rely  
4  
5 401 on. Further details of catchment areas will be needed to select suitable sampling sites  
6  
7 402 and this requires collaboration with water companies. Additionally, the precise  
8  
9 403 sensitivity of an ENV sample is dependent on many factors not considered in the  
10  
11 404 model but described elsewhere [2324]. Instead, we included a large range of  
12  
13 405 uncertainty and took this decision because of the lack of data to inform calculations  
14  
15 406 but this can be revisited should the data become available. The specified design  
16  
17 407 prevalence affects the estimates of sensitivity and as eradication approaches a more  
18  
19 408 stringent design prevalence may be warranted. Methodological developments may be  
20  
21 409 required to validate the approach, such as simulation. With these caveats in mind, it  
22  
23 410 should be noted that the exact risk probabilities may be uncertain but the relative  
24  
25 411 difference between LAs and mode of surveillance should still hold.  
26  
27  
28  
29  
30  
31  
32

## 33 413 Conclusion

34  
35 414  
36  
37 415 Surveillance for poliovirus is becoming increasingly complex owing to the different  
38  
39 416 modes of surveillance, and the changing risk of poliomyelitis. This research **is the first**  
40  
41 417 **attempts** to quantify the variation in poliovirus risk in a disease-free setting, and use of  
42  
43 418 these estimates to compare different modes of surveillance. ENV surveillance will  
44  
45 419 improve the sensitivity of surveillance, thus supporting the certification phase of polio  
46  
47 420 eradication.  
48  
49  
50  
51

52 421  
53  
54 422 **Financial support:** Funded by the Medical Research Council (MR/J014362/1) and  
55  
56 423 Bill and Melinda Gates Foundation (OPP1191821). The funder had no role in the  
57  
58 424 design, implementation or interpretation of the results.  
59  
60

1  
2  
3 425 **Acknowledgements:** The authors would like to thank the PHE convened Polio  
4  
5 426 Working Group which commissioned this work, Chris Thompson from Thames Water  
6  
7 427 who assisted with the guiding the modelling framework, Jonathon Cook from the  
8  
9 428 Office of National Statistics for providing country-level data from the International  
10  
11 429 Passenger Survey. Members of Vaccine Epidemiology Group at Imperial College  
12  
13 430 London have helpfully provided constructive feedback in developing the research,  
14  
15 431 along with fruitful discussions with Professor Paul Fine (LSHTM).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only

432

433 **References**

434

- 435 1. Salisbury, D. M., Ramsay, M. E., White, J. M. & Brown, D. W. Polio eradication:  
436 surveillance implications for the United Kingdom. *J. Infect. Dis.* 1997; 175 Suppl 1,  
437 S156-159.
- 438 2. Joce, R., Wood, D., Brown, D. & Begg, N. Paralytic Poliomyelitis in England and  
439 Wales, 1985-91. *Br. Med. J.* 1992; 305, 79–82.
- 440 3. WHO. 32<sup>ND</sup> meeting of the European regional commission for certification of  
441 poliomyelitis eradication (RCC). Available from: [http://www.euro.who.int/en/health-](http://www.euro.who.int/en/health-topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-the-european-regional-commission-for-certification-of-poliomyelitis-eradication-rcc-report-2018)  
442 [topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-](http://www.euro.who.int/en/health-topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-the-european-regional-commission-for-certification-of-poliomyelitis-eradication-rcc-report-2018)  
443 [the-european-regional-commission-for-certification-of-poliomyelitis-eradication-](http://www.euro.who.int/en/health-topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-the-european-regional-commission-for-certification-of-poliomyelitis-eradication-rcc-report-2018)  
444 [rcc-report-2018](http://www.euro.who.int/en/health-topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-the-european-regional-commission-for-certification-of-poliomyelitis-eradication-rcc-report-2018)
- 445 4. Manor, Y. *et al.* Intensified environmental surveillance supporting the response to  
446 wild poliovirus type 1 silent circulation in Israel, 2013. *Eurosurveillance.* 2014; 19,  
447 1–10.
- 448 5. Asghar, H. *et al.* Environmental surveillance for polioviruses in the global polio  
449 eradication initiative. *J. Infect. Dis.* 2014; 210, S294–S303.
- 450 6. Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-Derived  
451 Polioviruses. *J. Infect. Dis.* 2014; 210, S283-S293.
- 452 7. Macklin, G. *et al.* Prolonged Excretion of Poliovirus among Individuals with  
453 Primary Immunodeficiency Disorder: An Analysis of the World Health Organization  
454 Registry. *Front. Immunol.* 2017; 8, 1103.
- 455 8. PHE. National Guidelines for Clinical Management of Polio. (2019). Available  
456 from: <https://www.gov.uk/government/collections/polio-guidance-data-and-analysis>

- 1  
2  
3 457 9. 2011 Census - Office for National Statistics.  
4  
5  
6 458 <https://www.ons.gov.uk/census/2011census>.  
7  
8 459 10. ONS. International Passenger Survey. (2018). Available from:  
9  
10 460 <https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/househol>  
11  
12 461 [dandindividualsurveys/internationalpassengersurvey](https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/househol)  
13  
14 462 11. Martin, P. A. J., Cameron, A. R. & Greiner, M. Demonstrating freedom from  
15  
16 463 disease using multiple complex data sources 1: a new methodology based on  
17  
18 464 scenario trees. *Prev. Vet. Med.* 2007; 79, 71–97.  
19  
20 465 12. Cameron, A., Njeumi, F., Chibeu, D & Martin, T. Risk-based disease  
21  
22 466 surveillance. Available from: <http://www.fao.org/3/a-i4205e.pdf>  
23  
24 467 13. Minor, P. D. & Muir, P. Enteroviruses. In: Zuckerman AJ, Banatvala JE, Pattison  
25  
26 468 JR, Griffiths PD, Schoub BD, editors. in *Principles and practice of clinical virology*  
27  
28 469 467–490 (Wiley, 2004).  
29  
30 470 14. Mehndiratta, M. M., Mehndiratta, P. & Pande, R. Poliomyelitis. *The*  
31  
32 471 *Neurohospitalist* 2014; 4, 223–229.  
33  
34 472 15. Kadambari S, Bukasa A, Okike IO, Pebody R, Brown D, Gallimore C, Xerry J,  
35  
36 473 Sharland M, Ladhani SN. Enterovirus infections in England and Wales, 2000-2011:  
37  
38 474 the impact of increased molecular diagnostics. *Clin Microbiol Infect.* 2014  
39  
40 475 Dec;20(12):1289-96. doi: 10.1111/1469-0691.12753.  
41  
42 476 4516. Iturriza-Gómara, M., Megson, B. & Gray, J. Molecular detection and  
43  
44 477 characterization of human enteroviruses directly from clinical samples using RT-  
45  
46 478 PCR and DNA sequencing. *J. Med. Virol.* 2006; 78, 243–253.  
47  
48 479 4617. Majumdar, M. *et al.* Isolation of Vaccine-Like Poliovirus Strains in Sewage  
49  
50 480 Samples From the United Kingdom. *J. Infect. Dis.* 2018; 217, 1222–1230.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 481 [1718](#). Tiley, K. *et al.* What school-level and area-level factors influenced HPV and  
4  
5 482 MenACWY vaccine coverage in England in 2016/2017? An ecological study. *BMJ*  
6  
7 483 *Open* 2019; 9, e029087.
- 8  
9  
10 484 [1819](#). PHE. Latest health and travel advice for Hajj and Umrah. Available from:  
11  
12 485 <https://www.gov.uk/government/news/latest-health-and-travel-advice-for-hajj-and->  
13  
14 486 [umrah](https://www.gov.uk/government/news/latest-health-and-travel-advice-for-hajj-and-umrah)
- 15  
16  
17 487 [1920](#). Moran-Gilad, J., Kaliner, E., Gdalevich, M. & Grotto, I. Public health response  
18  
19 488 to the silent reintroduction of wild poliovirus to Israel, 2013-2014. *Clin. Microbiol.*  
20  
21 489 *Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* 2016; 22 Suppl 5, S140–  
22  
23 490 S145.
- 24  
25  
26 491 [210](#). Yakovenko, M. L. *et al.* The 2010 outbreak of poliomyelitis in Tajikistan:  
27  
28 492 epidemiology and lessons learnt. *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur.*  
29  
30 493 *Commun. Dis. Bull.* 2014; 19, 20706.
- 31  
32  
33 494 [2122](#). Wolff, C. *et al.* Progress toward laboratory containment of poliovirus after polio  
34  
35 495 eradication. *J. Infect. Dis.* 2014; 210, S454–S458.
- 36  
37  
38 496 [222-3](#). Dunn, G. *et al.* Twenty-Eight Years of Poliovirus Replication in an  
39  
40 497 Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. *PLoS*  
41  
42 498 *Pathog.* 2015; 11, e1005114.
- 43  
44  
45 499 [2324](#). Ranta, J., Hovi, T., Arjas, E. Poliovirus surveillance by examining sewage  
46  
47 500 water specimens: studies on detection probability using simulation models. *Risk*  
48  
49 501 *Anal.* 2001; 21, 1087–1096.
- 50  
51 502  
52  
53 503  
54  
55 504  
56  
57  
58  
59  
60

# Tables and Figures for “Surveillance Optimization to Detect Poliovirus in the Pre-Eradication Era: a Modelling Study of England and Wales”

**Table 1. Countries that have reported either wild or VDPVs between 2015-2017 and the reported number of movements between England and Wales.**

Country	Population size (million)	Cases of wild poliovirus (2015-2017)	Incidence of wild poliovirus (2015-2017) (per million per year)	Cases of VDPVs (2015-2017)	Incidence of VDPVs (2015-2017) (per million per year)	Combined incidence	Travel to England and Wales (2016)	Visitors from England and Wales (2016)
Afghanistan	34.6	47	0.45	0	0	<b>0.45</b>	ND	15,351
Pakistan	193.2	82	0.14	3	0.01	<b>0.15</b>	65,776	552,833
Nigeria	186	4	0.01	2	0	0.01	100,904	183,807
Madagascar	24.9	0	0	10	0.13	0.13	ND	8,289
Laos	6.8	0	0	11	0.54	0.54	ND	3,032
DRC	78.7	0	0	22	0.09	0.09	ND	ND
Syria	18.4	0	0	74	1.34	1.34	ND	ND
Guinea	12.1	0	0	7	0.19	0.19	ND	ND
Myanmar	52.9	0	0	2	0.01	0.01	ND	15,287

ND – no data, presumed to be very low

**Table 2. Estimates of surveillance probabilities used in the scenario tree analysis. The rationale behind the selected values are described in more detail in the Supplementary Material.**

Surveillance	AFP		ENT		ENV	
Model inputs	Probability	Estimate (95% CI)	Probability	Estimate (95% CI)	Probability	Estimate (95% CI)
Infection - wild	Pr(case <sub>AFP</sub> )	0.00531 (0.00412, 0.00668)	Pr(case <sub>ENT</sub> )	5.29e-05 (4.07e-05 6.74e-05)	Pr(shedding)	0.80
Infection - VDPV		0.000567 (0.000281, 0.000933)		As above		0.80
Notification	Pr(notif <sub>AFP</sub> )	0.9 (0.6, 0.99)	Pr(notif <sub>ENT</sub> )	0.9 (0.6, 0.99)	Pr(catchment)	varied
Sampling	Pr(sample <sub>AFP</sub> )	0.8 (0.5, 0.95)	Pr(sample <sub>ENT</sub> )	0.5 (0.1, 0.9)	Pr(sample)	0.80 (0.5, 0.90) <sup>1</sup>
Test	Pr(test <sub>AFP</sub> )	0.97 (0.95, 1.00)	Pr(test <sub>ENT</sub> )	0.97 (0.95, 1.00)	Pr(test <sub>ENV</sub> )	0.97 (0.95, 1.00)

<sup>1</sup> Monthly sampling

**Table 3. Summary of the Local Authorities that constitute over 50% of the estimated risk of poliovirus circulation in England and Wales. The parentheses A, B, and C refer to the ENV sampling strategies described in the results.**

Local Authority	County	Pentavalent Coverage <sup>1</sup>	Associated Water Company <sup>2</sup>	Pr(circulation)	% Total Estimated Risk	Population Size
Birmingham District (A)	West Midlands	94.8*	Severn Trent - Minworth	0.905	7.0%	1,073,045
Manchester District (A)	Greater Manchester	95.9*	United Utilities - Davyhulme	0.924	5.3%	503,127
Bradford District (A)	West Yorkshire	97.2	Yorkshire Water - Esholt	0.947	4.6%	522,452
Newham (B)	London Borough	94.2*	Thames Water - Beckton	0.896	3.8%	307,984
Redbridge (B)	London Borough	95.2*	Thames Water - Beckton	0.912	2.6%	278,970
Ealing (C)	London Borough	95.9*	Thames Water - Mogden	0.923	2.4%	338,449
Leeds District (C)	West Yorkshire	97.1	Yorkshire Water -	0.945	2.3%	751,485
Waltham Forest (B)	London Borough	92.1*	Thames Water - Beckton	0.864	2.2%	258,249
Luton (C)	Luton	96.3	Thames Water	0.932	1.9%	203,201
City of Nottingham (C)	Nottingham	94.7*	Severn Trent – Stoke Bardolph	0.904	1.9%	305,680
Hounslow (C)	London Borough	89.7*	Thames Water - Mogden	0.830	1.9%	253,957
Brent (C)	London Borough	93.1*	Thames Water - Mogden	0.879	1.8%	311,215
Sheffield District (C)	South Yorkshire	96.2	Yorkshire Water	0.929	1.5%	552,698
Slough (C)	Outer London	94.5*	Thames Water	0.901	1.5%	140,205
Hillingdon (C)	London Borough	95.1*	Thames Water - Mogden	0.911	1.5%	273,936
City of Westminster (B)	London Borough	75.9*	Thames Water - Beckton	0.675	1.4%	219,396
Caerdydd – Cardiff (C)	Wales	95.0*	Glas Cymru	0.909	1.4%	346,090
Kirklees District (C)	West Yorkshire	98.1	Yorkshire Water	0.963	1.3%	422,458
Barnet (C)	London Borough	92.1*	Thames Water - Mogden	0.864	1.3%	356,386
Greenwich (C)	London Borough	93.4*	Thames Water - Crossness	0.883	1.2%	254,557
Barking and Dagenham (B)	London Borough	90.5*	Thames Water - Beckton	0.840	1.2%	185,911

<sup>1</sup> Starred LAs indicate that the pentavalent coverage is below the national average. <sup>2</sup>Where possible the likely sewage treatment works is given.

1 **Figure 1.** Scenario tree structure for acute flaccid paralysis (AFP), enterovirus (ENT) and  
2 environmental (ENV) surveillance in England and Wales. Dashed circles indicate category nodes,  
3 squares indicate infection nodes, circles indicate detection nodes and hexagons indicate outcome  
4 nodes.

5 **Figure 2.** Estimated risk of poliovirus circulation in local authorities within A) England and Wales,  
6 and B) London. C) The estimated risk within each local authority is ordered by reducing risk and  
7 compared to the cumulative percentage of the population to illustrate that 50% of estimated risk is  
8 focussed within <20% of the population.





9 **Figure 3.** Estimates of the probability of being poliovirus free within England and Wales. The dark  
10 brown line is the median estimate and the lighter brown lines are the 2.5 and 97.5 percentile  
11 estimates. The arrow indicates when enterovirus surveillance was introduced. The dashed line  
12 indicates a 0.95 probability, which was reached by early 1996 for the wild virus analysis (VDPV is  
13 shown as a comparator).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Variation in poliovirus risk accounted for using Effective probability of infection (EPI)

Population Characteristics



A

1 Total Estimated Risk



10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35


36

37

38

39


40




B



C



Epidemiology and Infection  
**AFP & ENT surveillance**




London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

Year

# Supplementary Material for “Surveillance Optimization to Detect Poliovirus in the Pre-Eradication Era: a Modelling Study of England and Wales”

## 1. Vaccination coverage of the pentavalent vaccine

**Figure 1.** Average pentavalent coverage in children under 5 years of age by Local Authority within A) England and Wales and B) London Boroughs, 2011-2016. Local authorities that report coverage below 90% are highlighted.



## 2. Water companies and likely sewage treatment works serving high risk local authorities

### *Severn Trent water company*

Severn Trent water company serves cities such as Birmingham, Nottingham, Leicester and Wolverhampton, as described on their website (<https://www.severntrent.com/content/dam/stw-plc/water-resource-zones/WRMP-main-narrative.a.pdf>). Minworth sewage treatment works (in Sutton Coldfield) serves the area of Birmingham City. The sewage treatment works of Stoke Bardolph is the likely treatment works that serves the Nottingham area.

### *United Utilities*

The Greater Manchester area is served by United Utilities (<https://www.unitedutilities.com/help-and-support/wastewater-services/>). The treatment works that serves most of the Manchester area is the Davyhulme treatment works.

### *Yorkshire Water*


Yorkshire water serves Bradford, with Esholt treatment works being the main sewage treatment for this area (<https://www.yorkshirewater.com/waste-water-treatment-services/>). For Leeds, the likely sewage treatment facility is Knostrop Wastewater Treatment Works. For Sheffield the likely sewage treatment works is Woodhouse Mill Sewage Treatment Works.

### *Thames Water*

Thames water is the company that serves the Greater London area and some additional counties surrounding London. There are three main sewage treatment works; Beckton, Crossness and Mogden. The catchment of these treatment works has been well described by Thames Water (see figure), and can be used to approximate which would be sampled if carrying out surveillance of each population within the Local Authority.

### *Glas Cymru*

Glas Cymru is the water treatment company for Wales. The likely sewage treatment works for Cardiff is Llwyn Onn Sewage Works.



32  
33  
34

### 35 3. Estimation of the spatial variation in the potential for poliovirus circulation in 36 England and Wales

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

The probability of local poliovirus circulation (herein referred to as poliovirus circulation) is estimated. Within this context we are interested in circulation that may result in a poliomyelitis case. The basic reproduction number ( $R_0$  - the average number of secondary cases from one infected person within a totally susceptible population) is useful measure of transmissibility of an infectious disease. When  $R_0$  is greater than 1 the introduction of an infected individual may result in a large outbreak and if  $R_0 < 1$  a large outbreak is unlikely. For vaccines with sterilizing immunity the probability of a major epidemic is given by  $s = 1 - 1/(R_0(1 - c))$  where  $c$  refers to the proportion of the population immunised. Rather than sterilising immunity, the IPV (which is part of the pentavalent vaccine) reduces the infectiousness and duration of infectiousness of immunised individuals,<sup>1</sup> so the probability of a major epidemic requires some adaptation;  $s = 1 - 1/(R_0((1 - c) + chd))$  where  $h$  is the relative infectiousness of immunised individuals and  $d$  is the relative change in the duration of infectiousness.

54  
55  
56  
57  
58  
59  
60

The probability of major epidemic was estimated for each LA in England and Wales. To estimate the potential for poliovirus circulation the probability of circulation and the number of importation events ( $M_j$ ) are combined assuming a binomial process. The risk for LA  $i$   $\{i = 1, \dots, N\}$  was estimated by summing over all locations considered to be a potential source ( $j$ );

$$R_i = 1 - \sum_{j=1}^N (1 - s_i)^{M_j}. \quad \text{equation 2.1}$$

For ENV surveillance in England and Wales to be optimised, sampling should be prioritised within sewage catchment areas with LAs with the highest risk. Wastewater treatment in England and Wales consists of eleven companies that manage regions similar to counties. Analysis of the spatial variation in poliovirus risk does not fully align with the location of sewage catchment areas but we provide an indication of the LAs and corresponding water company, and where possible the sewage treatment works that should be sampled to capture wastewater from each LA. The risk of poliovirus circulation is assumed to vary between wild and VDPVs based on just the location of reported cases and migration between England and Wales and these countries.

The estimated number of importations of either wild or VDPV poliovirus ( $M$ ) is a function of the number of number of visitors to ( $N(i,j)$ ) and from each country ( $N(j,i)$ ), their vaccination status ( $v(i)$  and  $v(j)$ ), and the incidence of WPV and VDPVs within each country.

$$M_{WPV}(j) = N(i,j).I_{WPV}(j).(1 - v(i)) + N(j,i).I_{WPV}(j).(1 - v(j)) \quad \text{equation 2.2}$$

$$M_{VDPV}(j) = N(i,j).I_{VDPV}(j).(1 - v(i)) + N(j,i).I_{VDPV}(j).(1 - v(j)) \quad \text{equation 2.3}$$

The total number of movements are  $M_j = M_{WPV,j} + M_{VDPV,j}$ .

#### 4. Estimation of surveillance sensitivity

The methods for estimating the sensitivity of each mode of surveillance are first described.

For one poliovirus infection the sensitivity of detection through AFP surveillance ( $SeU_{AFP}$ ) is estimated by taking the product of each step in the detection pathway (ie. from the probability of an infection being symptomatic through to the probability of the diagnostic test being positive, see Figure 1). If the risk of infection is constant across all locations, the estimate of sensitivity remains relatively simple. However, if the risk of infection varies across settings, it is intuitive that sampling within high risk settings would be preferable to sampling in low risk settings, and so the sensitivity needs to be adjusted. Acknowledging that this adjustment is an approximation,<sup>2</sup> we can use estimates of relative risks. The effective probability of infection (EPI) is used to account for variation in poliovirus risk across the LAs. The EPI combines the adjusted risk and the herd prevalence,  $EPI_i = AR_i.P_h^*$ . The relative risks (RR), estimated in the previous section, and the proportion of the population (PrP) are used to calculate the adjusted risk (AR), by solving the simultaneous equations;

$$\frac{AR_i}{AR_j} = \frac{RR_i}{RR_j} \quad \text{equation 3.1}$$

$$AR_1.PrP_1 + \dots + AR_n.PrP_n = 1. \quad \text{equation 3.2}$$

High risk LAs will have an adjusted risk above 1.00 and consequently increased surveillance within these settings would have a more rapid improvement in the sensitivity of the entire

system. Combining these elements together, the sensitivity of detection through AFP surveillance is;

$$SeU_{AFP,i} = EPI_i \cdot Pr(case_{AFP}) \cdot Pr(notification_{AFP}) \cdot Pr(sample_{AFP}) \cdot Pr(test_{AFP})$$

To calculate the sensitivity of AFP within each LA in a given month ( $SSe_{AFP,i}$ ), we assume that all individuals ( $n$ ) within each LA are included in surveillance;

$$CSe_{AFP,i} = 1 - (1 - SeU_{AFP,i})^{n_i}$$

Similar calculations are done for enterovirus ( $CSe_{ENT,i}$ ) and environmental surveillance ( $CSe_{ENV,i}$ ). All probabilities include uncertainty which is carried through the calculations and the mean and 95% credible intervals are given. See section 5 for a description of how estimates for each element of surveillance were derived.

We then want to estimate the sensitivity across the entire system for each mode of surveillance. First we need to combine estimates LAs for each surveillance system;

$$CSe_{AFP} = 1 - \prod_{i=1}^M CSe_{AFP,i}$$

Then these values are used to estimate the surveillance sensitivity of the entire system;  $CSe = 1 - ((1 - CSe_{AFP})(1 - CSe_{ENT})(1 - CSe_{ENV}))$ .

As with other high-income countries sewage collects into a catchment area so maps from water companies can be used to determine the extent of population coverage if ENV is initiated at a specific sewage works. Composite samples are taken from the inlet of the sewage works and previous research suggests they have a high sensitivity to poliovirus if an individual is shedding within the last week.<sup>3</sup> Shedding studies have illustrated a high sensitivity of detecting poliovirus from just one composite sample and so the sensitivity of ENV is largely influenced by the frequency of sampling. If an individual sheds poliovirus for approximately 16 days,<sup>3</sup> poliovirus could be detected within sewage for up to 23 days from one individual, resulting in a monthly sampling frequency corresponding to a detection probability of  $(23+1)/30=0.80$ . The duration of shedding in IPV vaccinated individuals is lower,<sup>1</sup> but if more than one individual is shedding poliovirus the probability of detection would increase. To account for the known variation in shedding and uncertainty in the number of shedders the probability of detection is given wide confidence intervals and monte-carlo simulation is used to sample from these distributions (Table 3). Fortnightly sampling within one location would increase the detection probability to 1.00. Sensitivity of detection is thought to reduce with increasing sewage flow<sup>4</sup> and so sensitivity may be lower in sewage sites processing wastewater from a large (>100,000) population, but empirical studies that test this are lacking.

## 5. Estimation of the probability of being polio-free

Using the principal of the negative predictive value of a test, and assuming that testing has 100% specificity, the probability of being infection free within a given month ( $t$ ) is  $P(\text{free}_t) = (1 - P)/(1 - P.CSe_t)$ , where  $P$  is the prior for being infected and  $CSe$  refers to diagnostic sensitivity, which in this case is the sensitivity of the surveillance system. Each prior probability is the  $P(\text{free}_t)$  for the previous time period, which is a combination of being free during the previous time period and accounting for the probability of introduction. We also need to account for poliovirus introduction for each calendar month ( $P(\text{Intro}_t)$ ). The probability of being infection free within a calendar month is then given as;

$$P(\text{free}_{t-1}) = 1 - (P(\text{infect}_{t-1}) + P(\text{intro}_{t-1}) - P(\text{infect}_{t-1}).P(\text{intro}_{t-1})) \quad \text{equation 4.1}$$

$$P(\text{free}_t) = (1 - P(\text{free}_{t-1}))/((1 - P(\text{free}_{t-1})).CSe_t) \quad \text{equation 4.2}$$

Different sampling strategies are considered for ENV surveillance. The rate of poliovirus introduction is unknown, consequently the rate is estimated from approximating population movements to and from countries reporting poliomyelitis cases and the probability of shedding. From the International Passenger Survey (Figure 3) we can approximate the numbers of individuals that travel to and from countries reporting polio cases and combine this with the reported incidence of wild and VDPV within each country to provide an upper estimate of the rate of introduction. Low ( $1 \times 10^{-4}$ ), medium ( $1 \times 10^{-3}$ ) and high ( $5 \times 10^{-3}$ ) probabilities of poliovirus introduction per month were used to account the true value being unknown.




Figure 3. Estimates of the number of visits to and from countries that have reported poliomyelitis cases (IPS data).

## 6. Justification for probabilities used in the scenario tree modelling

In most probabilities estimated below, a mean and 95% confidence intervals are provided from the available data. These values were inputted to the model by specifying a beta distribution with parameters  $\alpha$  and  $\beta$ . Within the software R, the specific parameter values that correspond to the specified mean and 95% confidence intervals were provided using the library 'prevalence'.

### Acute Flaccid Paralysis (AFP) Surveillance

- $\text{Pr}(\text{case}_{\text{AFP}})$ : Of individuals infected with poliovirus Nathanson et al.<sup>5</sup> report that the probability of a clinical case varies by serotype; 0.005, 0.0005 and 0.0009 for serotypes 1, 2, and 3 respectively. A beta distribution with mean 0.005 and 95% CI 0.0005-0.009 encapsulates these estimated probabilities and the possible uncertainty in the values. As we estimate the sensitivity for wild poliovirus and vaccine-derived poliovirus separately, we use the estimates for serotype 1 and 2.
- $\text{Pr}(\text{notification}_{\text{AFP}})$ : A case of AFP caused by poliovirus is an acute condition where it is very likely in a high income setting that healthcare will be sought. However, there is little data to inform this probability so we have taken precautionary principle of using knowledge from all cases of AFP (including Guillian-Barre syndrome) within England and Wales.
- $\text{Pr}(\text{sample}_{\text{AFP}})$ : Stool sampling is recommended as part of the clinical investigation of all AFP cases. Within Salisbury et al.<sup>6</sup> of 0.54 of AFP cases had stool samples. Since this time clinical sampling has mostly likely improved, so we select a mean of 0.8 with confidence intervals ranging from 0.5-0.95.
- $\text{Pr}(\text{test}_{\text{AFP}})$ : Samples to be tested for poliovirus undergo rigorous laboratory testing where PCR is used to determine the presence of enterovirus in stool, CSF or throat swabs. Following a positive PCR virus culture, intratypic differentiation and sequence analysis will be carried out as per the WHO protocol. The testing is highly sensitive with reported sensitivities above 0.95 for ~100 RNA copies per microlitre for ITD 5.0 which is a similar protocol to that used in testing within England and Wales<sup>7</sup>. We specify a high probability of detection with a mean of 0.97 and 95% CI of 0.95-1.00.

### Enterovirus (ENT) Surveillance

- $\text{Pr}(\text{case}_{\text{ENT}})$ : Conditions such as aseptic meningitis are also clinical indicators of poliovirus infection in addition to acute flaccid myelitis. There are fewer reports of the probability of developing aseptic meningitis, but ~~Salisbury et al.<sup>6</sup> suggest that about 3% of case may lead to aseptic meningitis, and~~ Mehndiratta et al estimate that meningitis occurs in about 1% of cases,<sup>8</sup> although no distinction is made between serotype. Additionally, during a serotype 3 polio outbreak in Finland, nine cases of paralytic poliomyelitis were reported and one case of aseptic meningitis, which could

be used to suppose a 9:1 ratio of paralytic polio to aseptic meningitis.<sup>9</sup> Confidence intervals 0.01-0.05 were used to account for uncertainty in this estimate.

- Pr(notification<sub>ENT</sub>): Clinical disease associated with enterovirus infection is used as a proxy for the notification rate that might be associated with aseptic meningitis caused by poliovirus infection. Estimates are not available but it is assumed that health-seeking behaviours would be similar to that for poliovirus infection
- Pr(sample<sub>ENT</sub>): For clinical disease associated with enterovirus infection, Majumdar et al. <sup>9</sup> provide a description of current surveillance activities and report that a large proportion of clinical cases have microbiological samples (stool and CSF) that would enable culture of poliovirus. We assume an average probability of collecting a sample of 0.8 with wide confidence intervals (95% CI 0.5-0.95 to account for the large uncertainty in the estimate.
- Pr(test<sub>ENT</sub>): The microbiological protocol for clinical samples via ENT surveillance is the same as AFP diagnostics, so the same probabilities are used.

#### Environmental (ENV) Surveillance

- Pr(shedding<sub>ENV</sub>): We assume that all individuals infected with poliovirus shed poliovirus in stool.
- Pr(catchment<sub>ENV</sub>): As sewerage systems in England and Wales consist of a convergent sewer system, we can assume that all waste will eventually reach a sewage processing plant. Each local authority is assumed to have at most one sewage treatment plant that can be sampled for ENV surveillance. In many areas, for example London, one sewage treatment plant serves several local authorities. Within the framework, if a local authority is assumed to be sampled during ENV surveillance, we assume a probability of 0.8 that the infected individuals would be sampled (to account for time spent outside of the sewage catchment area).
- Pr(sample<sub>ENV</sub>): Sampling of wastewater is carried out using a composite sampler, which takes small samples of the wastewater over a 24 hour period <sup>9</sup>. If an individual sheds poliovirus for approximately 16 days,<sup>3</sup> poliovirus could be detected within sewage for up to 23 days from one individual, resulting in a monthly sampling frequency corresponding to a detection probability of  $(23+1)/30=0.80$ .
- Pr(test<sub>ENV</sub>): The microbiological protocol for clinical samples via ENV surveillance is similar as AFP diagnostics, with an added concentration step (2-phase separation) <sup>9</sup>. It is not thought that the concentration step reduced detection sensitivity, but the large amount of contamination from mixed sewage may reduce culture success of poliovirus.

#### References

1. Hird, T. R. & Grassly, N. C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. *PLoS Pathog.* **8**, (2012).

2. Cameron, A., Njeumi, F., Chibeu, D & Martin, T. RISK-BASED DISEASE SURVEILLANCE.
3. Lodder, W. J. *et al.* Feasibility of quantitative environmental surveillance in poliovirus eradication strategies. *Appl. Environ. Microbiol.* **78**, 3800–3805 (2012).
4. Hovi, T., Stenvik, M., Partanen, H. & Kangas, A. Poliovirus surveillance by examining sewage specimens. Quantitative recovery of virus after introduction into sewerage at remote upstream location. *Epidemiol. Infect.* **127**, 101–106 (2001).
5. Nathanson, N. & Kew, O. M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. *Am. J. Epidemiol.* **172**, 1213–1229 (2010).
6. Salisbury, D. M., Ramsay, M. E., White, J. M. & Brown, D. W. Polio eradication: surveillance implications for the United Kingdom. *J. Infect. Dis.* **175 Suppl 1**, S156-159 (1997).
7. Gerloff, N. *et al.* Diagnostic Assay Development for Poliovirus Eradication. *J. Clin. Microbiol.* **56**, (2018).
8. Mehndiratta, M. M., Mehndiratta, P. & Pande, R. Poliomyelitis. *The Neurohospitalist* **4**, 223–229 (2014).
9. [Simonen, ML, Roivainen, M, Iber, J, Burns, C & Hovi, T. Outbreak of poliomyelitis in Finland in 1984-85-Re-analysis of viral sequences using the current standard approach. \*Virus research.\* 2010. 147\(1\); 91-97. doi: 10.1016/j.virusres.2009.10.012](#)
109. Majumdar, M. *et al.* Isolation of Vaccine-Like Poliovirus Strains in Sewage Samples From the United Kingdom. *J. Infect. Dis.* **217**, 1222–1230 (2018).